Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Family with sequence similarity 114 member A1 (FAM114A1), also known as Protein NOXP20, encodes a cytoplasmic protein implicated in neuronal cell development and the regulation of melanocyte biology, particularly apoptosis, proliferation, and melanin synthesis[1][2][3]. FAM114A1 contains a caspase recruitment domain and is most abundantly expressed in the nervous system, as well as in the embryonic and adult brain[1]. It exerts a regulatory influence in various cell types including melanocytes and immune cells, and may act through the modulation of RACK1, an intracellular adaptor protein, particularly in controlling apoptosis in melanocytes[1][2]. Genetic and expression studies suggest roles in multiple diseases, including pigmentary disorders (vitiligo), autoimmune diseases (ankylosing spondylitis, autoimmune enteritis), liver fibrosis, and some cancers, where its expression serves as a prognostic biomarker[2]. The protein is multifaceted, but there is currently no evidence it functions as a typical druggable therapeutic target such as a receptor or enzyme[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Family with sequence similarity 114 member A1 (FAM114A1).